Increased drug delivery to the brain by P‐glycoprotein inhibition
暂无分享,去创建一个
C. Wandel | A. Wood | H. He | C Wandel | A J Wood | A J Sadeque | H He | S Shah | A. Sadeque | Selina Shah | Hauibing He
[1] R. Kim,et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.
[2] J. Sheller,et al. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. , 1999, The Journal of pharmacology and experimental therapeutics.
[3] G R Wilkinson,et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.
[4] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[5] T. MacDonald,et al. Treating diarrhoea. Children deserve special attention. , 1997, BMJ.
[6] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[7] M. Eichelbaum,et al. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. , 1995, British journal of clinical pharmacology.
[8] V. Nitsche,et al. Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). , 1995, International journal of clinical pharmacology and therapeutics.
[9] Y Chen,et al. Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.
[10] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[11] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[12] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[13] D. Breimer,et al. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans , 1991, Clinical pharmacology and therapeutics.
[14] T. Bhutta,et al. Loperamide poisoning in children , 1990, The Lancet.
[15] A. Pesce,et al. CONCOMITANT ADMINISTRATION OF CYCLOSPORIN AND KETOCONAZOLE IN RENAL TRANSPLANT RECIPIENTS , 1989, The Lancet.
[16] J. Dover,et al. INTERACTION BETWEEN CYCLOSPORIN AND RIFAMPICIN , 1984, The Lancet.
[17] Read Dj,et al. A clinical method for assessing the ventilatory response to carbon dioxide. , 1967 .
[18] K. Thummel,et al. In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.
[19] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[20] J. Endicott,et al. The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.
[21] D. Laurence,et al. Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.
[22] D. Read,et al. A clinical method for assessing the ventilatory response to carbon dioxide. , 1967, Australasian annals of medicine.